---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029860"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:12:21.312087+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nkarta to host conference call to discuss updated NKX101 clinical data on June 27

## Summary
- Press release on June 26, 2023 announces conference call for June 27, 2023 at 8:00 a.m. ET.
- Call to review updated clinical data from ongoing trial of NKX101, an allogeneic CAR NK cell therapy targeting NKG2D ligands.
- Company ticker NKTX; slides will be available on Nkarta's website.
- Replay of call archived for approximately four weeks.

## SEC filing metadata
- accession: 0000950170-23-029860
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000095017023029860/0000950170-23-029860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000095017023029860/nktx-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029860
- JSON: https://secwatch.observer/filing/0000950170-23-029860.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.